Literature DB >> 35710283

Contemporary Management of Refractory Angina.

Rebekah Lantz1, Odayme Quesada2, Georgia Mattingly1, Timothy D Henry3.   

Abstract

Refractory angina (RA) is defined as chest pain caused by coronary ischemia in patients on maximal medical therapy and is not amenable to revascularization despite advanced coronary artery disease (CAD). The long-term prognosis has improved with optimal medical therapy including risk factor modification. Still, patients are left with major impairment in quality of life and have high resource utilization with limited treatment options. We review the novel invasive and noninvasive therapies under investigation for RA.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angina; Coronary artery disease; Microvascular

Mesh:

Year:  2022        PMID: 35710283      PMCID: PMC9275781          DOI: 10.1016/j.iccl.2022.03.002

Source DB:  PubMed          Journal:  Interv Cardiol Clin        ISSN: 2211-7458


  80 in total

1.  Trial to show the impact of nicorandil in angina (IONA): design, methodology, and management.

Authors: 
Journal:  Heart       Date:  2001-06       Impact factor: 5.994

2.  Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization.

Authors:  D Mukherjee; K Comella; D L Bhatt; M T Roe; V Patel; S G Ellis
Journal:  Am Heart J       Date:  2001-07       Impact factor: 4.749

3.  The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina.

Authors:  Thomas J Povsic; Timothy D Henry; Jay H Traverse; F David Fortuin; Gary L Schaer; Dean J Kereiakes; Richard A Schatz; Andreas M Zeiher; Christopher J White; Duncan J Stewart; E Marc Jolicoeur; Theodore Bass; David A Henderson; Patricia Dignacco; Ziangoiong Gu; Hussein R Al-Khalidi; Candice Junge; Adel Nada; Andrea S Hunt; Douglas W Losordo
Journal:  JACC Cardiovasc Interv       Date:  2016-08-08       Impact factor: 11.195

4.  Angiographic quantification of diffuse coronary artery disease: reliability and prognostic value for bypass operations.

Authors:  M M Graham; R J Chambers; R F Davies
Journal:  J Thorac Cardiovasc Surg       Date:  1999-10       Impact factor: 5.209

5.  Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study.

Authors:  Michael E Farkouh; Michael Domanski; George D Dangas; Lucas C Godoy; Michael J Mack; Flora S Siami; Taye H Hamza; Binita Shah; Giulio G Stefanini; Mandeep S Sidhu; Jean-François Tanguay; Krishnan Ramanathan; Samin K Sharma; John French; Whady Hueb; David J Cohen; Valentin Fuster
Journal:  J Am Coll Cardiol       Date:  2018-11-11       Impact factor: 24.094

6.  The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes.

Authors:  R R Arora; T M Chou; D Jain; B Fleishman; L Crawford; T McKiernan; R W Nesto
Journal:  J Am Coll Cardiol       Date:  1999-06       Impact factor: 24.094

Review 7.  Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies.

Authors:  Guglielmo Gallone; Luca Baldetti; Georgios Tzanis; Mario Gramegna; Azeem Latib; Antonio Colombo; Timothy D Henry; Francesco Giannini
Journal:  JACC Cardiovasc Interv       Date:  2020-01-13       Impact factor: 11.195

Review 8.  Depression and cardiac disease: a review.

Authors:  Christopher M Celano; Jeff C Huffman
Journal:  Cardiol Rev       Date:  2011 May-Jun       Impact factor: 2.644

9.  Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials.

Authors:  Timothy D Henry; Cindy L Grines; Matthew W Watkins; Nabil Dib; Gerald Barbeau; Randall Moreadith; Tony Andrasfay; Robert L Engler
Journal:  J Am Coll Cardiol       Date:  2007-08-24       Impact factor: 24.094

Review 10.  Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair-A Systematic Review.

Authors:  Balaj Rai; Janki Shukla; Timothy D Henry; Odayme Quesada
Journal:  Cells       Date:  2021-05-08       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.